



# SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 7

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

|                         |  |
|-------------------------|--|
| <b>Product Name</b>     | Antivenin (Micrurus fulvius), North American Coral Snake Antivenin |
| <b>Product Code(s)</b>  | PZ01592  |
| <b>Synonyms</b>         | CSAV   |
| <b>Trade Name:</b>      | Antivenin (Micrurus fulvius), North American Coral Snake Antivenin |
| <b>Item Code</b>        | H000200637, H000401149   |
| <b>Chemical Family:</b> | Not determined   |

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

|                        |                        |
|------------------------|------------------------|
| <b>Recommended Use</b> | Pharmaceutical product |
|------------------------|------------------------|

### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc  
66 Hudson Boulevard East  
New York, New York 10001  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

|                       |                        |
|-----------------------|------------------------|
| <b>E-mail address</b> | pfizer-MSDS@pfizer.com |
|-----------------------|------------------------|

### 1.4. Emergency telephone number

|                            |  |
|----------------------------|--|
| <b>Emergency Telephone</b> | Chemtrec 1-800-424-9300 International Chemtrec (24 hours): +1-703-527-3887 |
|----------------------------|--|

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

#### OSHA Classification

##### Hazards not otherwise classified (HNOC)

Not applicable

##### Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

### 2.2. Label elements

|                          |   |
|--------------------------|---|
| <b>Signal word</b>       | Not classified  |
| <b>Hazard statements</b> | Not classified in accordance with international standards for workplace safety. |

### 2.3. Other hazards

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 2 / 13

Version 7

**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**PBT & vPvB** The product does not contain any substance(s) classified as PBT or vPvB.

**Endocrine Disruptor Information** This product does not contain any known or suspected endocrine disruptors.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

**Substances** Not applicable

### 3.2 Mixtures

Hazardous

| Chemical name   | Weight-% | REACH registration number | EC No (EU Index No) | Classification according to Regulation (EC) No. 1272/2008 [CLP]   | Specific concentration limit (SCL)  | M-Factor          | M-Factor (long-term) |
|---|----------|---------------------------|---------------------|---|---|-------------------|----------------------|
| Serum for Coral Snake Antivenin (CAS #: NOT ASSIGNED) | *        |                           | Not Listed          | Not classified  | Not classified  | No data available | No data available    |
| PHENOL (CAS #: 108-95-2)                              | 0.25     |                           | 203-632-7           | Acute Tox. 3 (H301)<br>STOT RE 2 (H373)<br>Muta. 2 (H341)<br>Skin Corr.1B (H314)<br>Acute Tox. 3 (H331) | Eye Irrit. 2 :: 1%<=C<3%<br>Skin Corr. 1B :: C>=3%<br>Skin Irrit. 2 :: 1%<=C<3% | No data available | No data available    |

**Full text of H- and EUH-phrases: see section 16**

**Acute Toxicity Estimate** No information available

| Chemical name   | Oral LD50 mg/kg | Dermal LD50 mg/kg | Inhalation LC50 - 4 hour - dust/mist - mg/L | Inhalation LC50 - 4 hour - vapor - mg/L | Inhalation LC50 - 4 hour - gas - ppm |
|-----------------|-----------------|-------------------|---|---|--------------------------------------|
| PHENOL 108-95-2 | 340             | 630               | No data available                           | No data available                       | No data available                    |

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 3 / 13

Version 7

## Additional information

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

|              |  |
|--------------|--|
| Inhalation   | Remove to fresh air. Seek immediate medical attention/advice.  |
| Eye contact  | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.   |
| Skin contact | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.  |
| Ingestion    | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

### 4.2. Most important symptoms and effects, both acute and delayed

|                                     |  |
|-------------------------------------|--|
| Most important symptoms and effects | For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. |
|-------------------------------------|--|

### 4.3. Indication of any immediate medical attention and special treatment needed

|                    |       |
|--------------------|-------|
| Note to physicians | None. |
|--------------------|-------|

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

|                              |   |
|------------------------------|---|
| Suitable Extinguishing Media | Dry chemical, CO2, alcohol-resistant foam or water spray. |
|------------------------------|---|

### 5.2. Special hazards arising from the substance or mixture

|  |  |
|--|--|
| Specific hazards arising from the chemical | Fine particles (such as mists) may fuel fires/explosions.    |
| Hazardous combustion products              | Formation of toxic gases is possible during heating or fire. |

#### Explosion data

|                                  |                           |
|----------------------------------|---------------------------|
| Sensitivity to mechanical impact | No information available. |
| Sensitivity to static discharge  | No information available. |

### 5.3. Advice for firefighters

|  |  |
|--|--|
| Special protective equipment and precautions for fire-fighters | Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment. |
|--|--|

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

|                      |   |
|----------------------|---|
| Personal precautions | Personnel involved in clean-up should wear appropriate personal protective equipment (see |
|----------------------|---|

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 4 / 13

Version 7

**For emergency responders** Section 8). Minimize exposure.  
Use personal protection recommended in Section 8.

## **6.2. Environmental precautions**

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## **6.3. Methods and material for containment and cleaning up**

**Methods for containment** Prevent further leakage or spillage if safe to do so.  
**Methods for cleaning up** Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.  
**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

## **6.4. Reference to other sections**

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### **7.1. Precautions for safe handling**

**Advice on safe handling** Restrict access to work area. Avoid open handling. Ground and bond all bulk transfer equipment. Minimize dust generation. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.  
**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### **7.2. Conditions for safe storage, including any incompatibilities**

**Storage Conditions** Store as directed by product packaging.

### **7.3. Specific end use(s)**

**Specific use(s)** Pharmaceutical drug product.

## **Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### **8.1. Control parameters**

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **PHENOL**

ACGIH

ACGIH - Skin Absorbers

ACGIH TLV

250 mg/g creatinine - urine (Phenol with hydrolysis) - end of shift  
Skin - potential significant contribution to overall exposure by the cutaneous route  
TWA: 5 ppm

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 5 / 13

Version 7

|                |   |
|----------------|---|
| Austria        | pSk<br>TWA-TMW: 2 ppm;<br>TWA-TMW: 8 mg/m <sup>3</sup> ;<br>STEL-KZGW: 4 ppm (4 X 15 min);<br>STEL-KZGW: 16 mg/m <sup>3</sup> (4 X 15 min);                     |
| Bulgaria       | Sk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;   |
| Czech Republic | Sk<br>7.5 mg/m <sup>3</sup><br>Ceiling: 15 mg/m <sup>3</sup><br>D*  |
| Denmark        | TWA: 1 ppm;<br>TWA: 4 mg/m <sup>3</sup> ;<br>STEL: 16 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;   |
| Estonia        | pSk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 16 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;  |
| European Union | Sk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;   |
| Finland        | pSk<br>1.3 mmol/L (urine - Total phenol after the shift)  |
| Finland        | TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;   |
| France         | pSk   |
| Germany DFG    | 7.8 mg/m <sup>3</sup>   |
| Germany TRGS   | Sk<br>TWA-AGW; 2 ppm (exposure factor 2);<br>TWA-AGW; 8 mg/m <sup>3</sup> (exposure factor 2);  |
| Germany DFG    | Sk<br>120 mg/g Creatinine (urine - Phenol (after hydrolysis) end of exposure or shift)  |
| Hungary        | 200 mg/L - BLW (end of exposure or end of shift) urine<br>TWA-AK: 2 ppm;<br>TWA-AK: 8 mg/m <sup>3</sup> ;<br>STEL-CK: 4 ppm;<br>STEL-CK: 16 mg/m <sup>3</sup> ; |
| Ireland        | pSk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;  |
| Italy MDLPS    | pSk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;  |

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 6 / 13

Version 7

|   |   |
|---|---|
| Latvia  | pSk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;  |
| Netherlands                                     | pSk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;  |
| Poland  | Sk<br>TWA-NDS: 7.8 mg/m <sup>3</sup> ;<br>STEL-NDSch: 16 mg/m <sup>3</sup> ;  |
| Romania   | Sk<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;   |
| Russia  | Sk<br>TWA: 0.3 mg/m <sup>3</sup><br>MAC: 1 mg/m <sup>3</sup>  |
| Slovakia  | Skin<br>TWA: 2 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>Ceiling: 16 mg/m <sup>3</sup> ;  |
| Spain   | pSk<br>120 mg/g Creatinine  |
| Spain   | TWA-(VLA-ED): 2 ppm;<br>TWA-(VLA-ED): 8 mg/m <sup>3</sup> ;<br>STEL (VLA-EC): 4 ppm;<br>STEL (VLA-EC): 16 mg/m <sup>3</sup> ;   |
| Switzerland                                     | pSk<br>TWA-MAK: 5 ppm; aerosol, vapour<br>TWA-MAK: 19 mg/m <sup>3</sup> ; aerosol, vapour<br>STEL-KZGW: 5 ppm; aerosol, vapour<br>STEL-KZGW: 19 mg/m <sup>3</sup> ; aerosol, vapour |
| OSHA - Final PELs - Skin Notations:<br>OSHA PEL | Sk<br>prevent or reduce skin absorption<br>TWA: 5 ppm<br>TWA: 19 mg/m <sup>3</sup><br>(vacated) TWA: 5 ppm<br>(vacated) TWA: 19 mg/m <sup>3</sup>                                   |
| United Kingdom                                  | dSk<br>Sdv<br>TWA: 2 ppm;<br>TWA: 7.8 mg/m <sup>3</sup> ;<br>STEL: 4 ppm;<br>STEL: 16 mg/m <sup>3</sup> ;<br>pSk  |

**Pfizer Occupational Exposure Band (OEB) Statement:** The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 7 / 13

Version 7

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Wear impervious disposable protective clothing to prevent skin contact. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.). Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

|                |                           |
|----------------|---------------------------|
| Appearance     | Lyophilized powder        |
| Physical state | Powder                    |
| Color          | No information available  |
| Odor           | No information available. |
| Odor threshold | No information available  |

#### Property

Melting point / freezing point  
Boiling point or initial boiling point and boiling range  
Flammability (solid, gas)  
Lower and upper explosion limit/flammability limit

#### Values

No data available  
No data available  
No data available

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 8 / 13

Version 7

|                                 |                          |
|---------------------------------|--------------------------|
| Lower explosion limit           | No data available        |
| Upper explosion limit           | No data available        |
| Flash point                     | No data available        |
| Autoignition temperature        | No data available        |
| Decomposition temperature       | No data available        |
| SADT (°C)                       | No data available        |
| pH                              | No data available        |
| pH (as aqueous solution)        | No data available        |
| Kinematic viscosity             | No data available        |
| Dynamic viscosity               | No data available        |
| Solubility                      | No data available        |
| Vapor pressure                  | No data available        |
| Density and/or relative density | No data available        |
| Bulk density                    | No data available        |
| Liquid Density                  | No data available        |
| Vapor density                   | No data available        |
| Particle characteristics        |                          |
| Particle Size                   | No information available |
| Particle Size Distribution      | No information available |

## 9.2. Other information

|                   |         |
|-------------------|---------|
| Molecular formula | Mixture |
| Molecular weight  | Mixture |

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

|            |                           |
|------------|---------------------------|
| Reactivity | No information available. |
|------------|---------------------------|

### 10.2. Chemical stability

|           |                                 |
|-----------|---------------------------------|
| Stability | Stable under normal conditions. |
|-----------|---------------------------------|

#### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

|                                    |                           |
|------------------------------------|---------------------------|
| Possibility of hazardous reactions | No information available. |
|------------------------------------|---------------------------|

### 10.4. Conditions to avoid

|                     |  |
|---------------------|--|
| Conditions to avoid | Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge. |
|---------------------|--|

### 10.5. Incompatible materials

|                        |  |
|------------------------|--|
| Incompatible materials | As a precautionary measure, keep away from strong oxidizers. |
|------------------------|--|

### 10.6. Hazardous decomposition products

|                                  |                    |
|----------------------------------|--------------------|
| Hazardous decomposition products | No data available. |
|----------------------------------|--------------------|

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008



# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 9 / 13

Version 7

|  |  |
|--|--|
| <b>General Information:</b>              | Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients   |
| <b>Short term</b>                        | May cause skin irritation. May be harmful if absorbed through the skin. (based on components)  |
| <b>Known Clinical Effects:</b>           | Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Serious allergic reactions, including anaphylaxis, have been reported. Based on human experience, possible adverse effects following exposure to this compound may include flushing, itching, hives, redness and swelling of the skin (urticaria), shortness of breath (dyspnea), blue appearance (cyanosis) and vomiting. |
| <b>Acute toxicity</b>                    | Based on available data, the classification criteria are not met.  |
| <b>Serious eye damage/eye irritation</b> | Based on available data, the classification criteria are not met.  |
| <b>Skin corrosion/irritation</b>         | Based on available data, the classification criteria are not met.  |
| <b>Respiratory or skin sensitization</b> | Based on available data, the classification criteria are not met.  |
| <b>STOT - single exposure</b>            | Based on available data, the classification criteria are not met.  |
| <b>STOT - repeated exposure</b>          | Based on available data, the classification criteria are not met.  |
| <b>Reproductive toxicity</b>             | Based on available data, the classification criteria are not met.  |
| <b>Germ cell mutagenicity</b>            | Based on available data, the classification criteria are not met.  |
| <b>Carcinogenicity</b>                   | Based on available data, the classification criteria are not met.  |
| <b>Aspiration hazard</b>                 | Based on available data, the classification criteria are not met.  |

## **Acute Toxicity: (Species, Route, End Point, Dose)**

### **PHENOL**

Rat Oral LD50 317 mg/kg  
Rat Dermal LD50 525 mg/kg  
Rabbit Dermal LD50 630 mg/kg  
Mouse Oral LD50 270 mg/kg

| Chemical name | Oral LD50           | Dermal LD50            | Inhalation LC50 |
|---------------|---------------------|------------------------|-----------------|
| PHENOL        | = 340 mg/kg ( Rat ) | = 630 mg/kg ( Rabbit ) | -               |

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **PHENOL**

2 Generation Reproductive Toxicity Rat Oral 1000 ppm NOAEL No effects at maximum dose  
Embryo / Fetal Development Rat Oral 120 mg/kg LOAEL Fetotoxicity, Not Teratogenic  
Fertility and Embryonic Development Rat Oral 53 mg/kg LOAEL Maternal Toxicity, Fetotoxicity, Not Teratogenic  
Embryo / Fetal Development Rat Intraperitoneal 200 mg/kg NOAEL No effects at maximum dose

## **Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **PHENOL**

103 Week(s) Rat Oral 5,000 ppm NOAEL Not carcinogenic  
103 Week(s) Mouse Oral 5,000 ppm NOAEL Not carcinogenic

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### **PHENOL**

IARC

Group 3

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 10 / 13

Version 7

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## 11.2.2. Other information

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties of the formulation have not been investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### **PHENOL**

*Selenastrum capricornutum* (Green Alga) EC50 96 hours 150 mg/L  
*Pimephales promelas* (Fathead Minnow) LC50 96 24 mg/L  
*Oncorhynchus mykiss* (Rainbow Trout) LC50 96 hours 8.9 mg/L  
*Lepomis macrochirus* (Bluegill Sunfish) LC50 96 Hours 23.88 mg/L  
*Daphnia magna* (Water Flea) LC50 48 hours 13 mg/L

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

#### **PBT and vPvB assessment**

| Chemical name | PBT and vPvB assessment |
|---------------|-------------------------|
| PHENOL        | Not PBT/vPvB            |

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## **Section 13: DISPOSAL CONSIDERATIONS**

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 11 / 13

Version 7

## 13.1. Waste treatment methods

### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

| Chemical name | RCRA - F Series Wastes | RCRA - K Series Wastes | RCRA - P Series Wastes | RCRA - U Series Wastes |
|---------------|------------------------|------------------------|------------------------|------------------------|
| PHENOL        | -                      | -                      | -                      | U188                   |

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is not regulated for transportation / carriage.

UN number: Not applicable  
UN proper shipping name: Not applicable  
Transport hazard class(es): Not applicable  
Packing group: Not applicable  
Environmental Hazard(s): Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Serum for Coral Snake Antivenin  
CERCLA/SARA Section 313 de minimus % Not Listed  
California Proposition 65 Not Listed  
EINECS Not Listed  
PHENOL  
CERCLA/SARA Section 313 de minimus % 1.0 %  
Hazardous Substances RQs 1000 lb  
California Proposition 65 Not Listed  
TSCA Present  
EINECS 203-632-7  
AICS Present  
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) Schedule 5  
Schedule 6  
Schedule 2  
Schedule 4

### National regulations

| Chemical name | French RG number |
|---------------|------------------|
| PHENOL        | RG 14            |

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 12 / 13

Version 7

108-95-2

## Germany

### **Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

| Chemical name      | Number | Class   |
|--------------------|--------|---------|
| PHENOL<br>108-95-2 | 5.2.5  | Class I |

TRGS 905

Not applicable

## Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material**

Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20**

Not applicable

**Major Accidents Ordinance SR 814.012**

Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### **Authorizations and/or restrictions on use:**

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

| Chemical name      | Restricted substance per REACH<br>Annex XVII | Substance subject to authorization per<br>REACH Annex XIV |
|--------------------|--|---|
| PHENOL<br>108-95-2 | 75   | -   |

## **Persistent Organic Pollutants**

Not applicable

## **Ozone-depleting substances (ODS) Regulation (EU) 2024/590**

Not applicable.

## **Explosives Precursors Marketing and Use (2019/1148)**

Not applicable

## Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

# SAFETY DATA SHEET

Product Name Antivenin (Micrurus fulvius), North American Coral Snake  
Antivenin  
Revision date 16-Jun-2025

Page 13 / 13

Version 7

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## **15.2. Chemical safety assessment**

**Chemical Safety Report** No information available

## **Section 16: OTHER INFORMATION**

### **Key or legend to abbreviations and acronyms used in the safety data sheet**

#### **Full text of any hazard and/or precautionary statements referred to under Sections 2-15**

H314 - Causes severe skin burns and eye damage H301 - Toxic if swallowed H341 - Suspected of causing genetic defects H331 - Toxic if inhaled H373 - May cause damage to organs through prolonged or repeated exposure

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.

**Reason for revision** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

**Revision date** 16-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**